Associated Papers
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.
Sahin IH et al.
Npj Precision Oncology, 2026
Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.
Ree AH et al.
British Journal of Cancer, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Synonymous Variants of Potential Significance Identified by a 52-Gene Clinical Sequencing Panel in Non-Small Cell Lung Cancer.
Varty K et al.
Genes, Chromosomes & Cancer, 2026
Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Chibaudel B et al.
International Journal of Molecular Sciences, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials.
Navarro-Jiménez M et al.
Npj Precision Oncology, 2025
Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.
Ianniello M et al.
Journal of Translational Medicine, 2025
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
The Impact of RAS/BRAF Mutation on Pathological Complete Response After Total Neoadjuvant Therapy in Rectal Cancer.
Aboelmaaty S et al.
Annals of Surgical Oncology, 2025
The pathogenic mutations in smokers with non-small cell lung cancer: a next-generation sequencing study.
Yan S et al.
Translational Lung Cancer Research, 2025
Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.
Waliany S et al.
Clinical Lung Cancer, 2025
Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes.
Toriyama K et al.
The Journal of Pathology, 2025
The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients.
Abrehdari-Tafreshi Z et al.
Biochemical Genetics, 2024
Integrative multi-omics profiling of colorectal cancer from a Hispanic/Latino cohort of patients.
Waldrup B et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.
Mosaferi Z et al.
Journal of Gastrointestinal Cancer, 2024
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Histological evidence of MAPK pathway activation across subtypes of adult orbital xanthogranulomatous disease irrespective of the detection of oncogenic mutations.
Detiger SE et al.
Clinical Immunology (orlando, Fla.), 2024
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients-Case Series and Literature Review.
Popescu I et al.
Journal of Personalized Medicine, 2024
Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer.
Lund-Andersen C et al.
Journal of Translational Medicine, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO).
Pizzutilo EG et al.
Esmo Open, 2024
LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer.
Lagoudaki ED et al.
Cancers, 2024
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
Bando H et al.
Cancer Science, 2024
RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review.
Benmokhtar S et al.
Clinical Medicine Insights. Oncology, 2024
The rapidly changing field of predictive biomarkers of non-small cell lung cancer.
Tóth LJ et al.
Pathology Oncology Research : Por, 2024
KRAS and BRAF Mutation Rates and Survival Outcomes in Colorectal Cancer in an Ethnically Diverse Patient Cohort.
Habashy P et al.
International Journal of Molecular Sciences, 2023
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer.
Fernández Montes A et al.
The Oncologist, 2023
Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer.
Aktar S et al.
Genes, 2023
Generation of novel complete HLA class I monoallelic cell lines used in an MHC stabilization assay for neoantigen evaluation.
Iizuka A et al.
Oncology Letters, 2023
KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.
Martianov AS et al.
International Journal of Molecular Sciences, 2023
Comparative study of the genomic landscape and tumor microenvironment among large cell carcinoma of the lung, large cell neuroendocrine of the lung, and small cell lung cancer.
Li F et al.
Medicine, 2023
Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.
Veccia A et al.
Targeted Oncology, 2023
Gastrointestinal Stromal Tumours (GISTs) with KRAS Mutation: A Rare but Important Subset of GISTs.
Mullen D et al.
Case Reports in Gastrointestinal Medicine, 2023
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Lee JK et al.
Npj Precision Oncology, 2022
Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples.
Gumà J et al.
Cancers, 2022
Decoding molecular programs in melanoma brain metastases.
Radke J et al.
Nature Communications, 2022
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics.
Roma C et al.
Diagnostics (basel, Switzerland), 2022
[Laser microdissection for the analysis of molecular heterogeneity in colorectal cancer].
Maag N et al.
Pathologie (heidelberg, Germany), 2022
Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.
Murphy BM et al.
Nature Communications, 2022
Multivariate Risk Analysis of RAS, BRAF and EGFR Mutations Allelic Frequency and Coexistence as Colorectal Cancer Predictive Biomarkers.
Ionescu A et al.
Cancers, 2022
Potential genetic biomarker of Saudi Arabian patients with colorectal cancer.
Younis NS et al.
European Review for Medical and Pharmacological Sciences, 2022
Rapid Multiplex Strip Test for the Detection of Circulating Tumor DNA Mutations for Liquid Biopsy Applications.
Kalligosfyri PM et al.
Biosensors, 2022
The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients.
Yang Y et al.
Translational Lung Cancer Research, 2022
Frequency and Clinicopathological Characteristics of Patients With KRAS/BRAF Double-Mutant Colorectal Cancer: An In Silico Study.
Uchida S et al.
Pathology Oncology Research : Por, 2022
KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients.
Wang S et al.
Frontiers in Molecular Biosciences, 2022
Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer.
Taniguchi F et al.
Future Science Oa, 2021